Great Hill Partners, a private equity firm that invests in high-growth, disruptive companies has made a $100 million Series F minority investment in IVX Health, a national provider of outpatient infusion centers. Great Hill joins IVX Health’s existing investors including Linden Structured Capital, McKesson Ventures, Health Velocity Capital, and Nueterra Capital.
IVX Health offers an alternative to hospital-based infusion and injection services.
“Our primary goal has always been to provide world-class service and clinical excellence to the patients we serve,” said Doug Ghertner, CEO of IVX Health. “IVX and Great Hill both see an inflection point in infusion therapy, as the growth in diagnosed autoimmune conditions and trends toward patient choice have aligned with an uptick in innovative new therapies. Many patients are unfortunately still left with few options for receiving this life-changing care, often within a crowded infusion room of a hospital – and that’s where we come in. We are confident that Great Hill’s investment and deep domain expertise will help us address this shortage of care options by enabling IVX to bring our unique clinical model and patient-centered amenities to an even broader universe of patients.”
“IVX Health is disrupting a distinct and rapidly growing healthcare vertical – biologic infusion and injection therapy – in unique ways that are driving tangible efficiencies for the U.S. healthcare system as a whole,” said Mark Taber, a managing director at Great Hill Partners. “We are excited to play a strategic, supporting role in fueling IVX Health’s next phase of growth as it enters new markets and collaborates with other providers in the healthcare ecosystem to drive value while continuing to redefine the care experience for its patients and referring providers.”
In connection with the investment, Taber will join IVX Health’s board of directors.
Evercore served as financial advisor to IVX Health and TripleTree LLC served as financial advisor to Great Hill.